Program
ABBV-7828
A development code.
In AbbVie's pipeline, JAK1i
. Its studies are led by AbbVie.
Furthest: phase 1, since Sep 28, 20261 company-led study, 1 open or runningNext primary completion: May 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 11 open or running | phase 1since Sep 28, 2026 | Sep 28, 2026 | May 2027phase 1 · NCT07856706 |
- Named in AbbVie’s own pipeline as
ABBV-7828
, phase 1, as of Jul 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 28, 2026First study: phase 1 study in Healthy SubjectsFirst studyNCT07856706 · 60 planned · United States
Ahead
- May 2027Primary completion: phase 1 study in Healthy SubjectsNCT07856706
TargetBeta
“JAK1i”the company's pipeline, read by Claude · source
Other programs on JAK1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ruxolitinibrule | Incyte | phase 4 | 95 |
| tofacitinibrule | Pfizer | phase 4 | 94 |
| upadacitinibrule | AbbVie | phase 4 | 64 |
| baricitinibrule | Eli Lilly | phase 4 | 59 |
| filgotinib maleaterule | Eisai | phase 4 | 2 |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 46 |
| jaktinibrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 31 |
| abrocitinibrule | Pfizer | phase 3 | 30 |
| ivarmacitinibrule | Jiangsu HengRui Medicine | phase 3 | 25 |
| brepocitinibrule | Pfizer | phase 3 | 25 |
| delgocitinibrule | LEO Pharma | phase 3 | 21 |
| momelotinibrule | GlaxoSmithKline | phase 3 | 17 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07856706Healthy Subjects · United States | 1 | Recruiting | May 2027 | 60 |
How it is read
Names in the registry
- “ABBV-7828”, 1 entry
Codes read as this program: ABBV7828.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.